Skip to main content
Download PDF

Test characteristics and potential impact of the urine LAM lateral flow assay in HIV-infected outpatients under investigation for TB and able to self-expectorate sputum for diagnostic testing

BMC Infectious Diseases volume 15, Article number: 262 (2015) Cite this article

Abstract

Background

The commercially available urine LAM strip test, a point-of-care tuberculosis (TB) assay, requires evaluation in a primary care setting where it is most needed. There is currently inadequate data to guide implementation in TB and HIV-endemic settings.

Methods

Adult HIV-infected outpatients with suspected pulmonary TB able to self-expectorate sputum from four primary clinics in South Africa, Zambia and Tanzania underwent diagnostic evaluation [sputum smear microscopy, Xpert-MTB/RIF, and culture (reference standard)] as part of a prospective parent study. Urine LAM testing (grade-2 cut-point) was performed on archived samples. Performance characteristics of LAM alone or in combination with sputum—based diagnostics were evaluated. Potential impact on 2 and 6-month morbidity (TBscore), patient dropout rates, and prognosis (death/ loss to follow-up) were evaluated.

Results

Among 583 participants with suspected TB that were HIV-infected or refused testing, the overall LAM sensitivity (95 % CI; n/N) and in the CD4 ≤ 100 cells/mm3 sub-group was 22.7 % (16.6-28.7; 41/181) and 30.4 % (17.1-43.7; 14/46), respectively. Overall specificity was 93.0 % (90.5-95.6; 361/388). Amongst culture-positive TB cases, adjunctive LAM testing did not improve the sensitivity of either sputum Xpert-MTB/RIF [78.2 % (69.8-86.7; 72/92) versus 76.1 % (67.4-84.8; 70/92), p = 0.7] or smear-microscopy [56.2 % (45.9-66.5; 50/89) versus 43.8 % (33.5-54.1; 39/89), p = 0.1). Clinic-based LAM, as an adjunct to either smear microscopy or Xpert MTB/RIF same-day testing, would neither have decreased patient dropout, nor increased same-day treatment initiation in this clinical setting where same-day chest radiography was available. LAM positivity was associated with 6-month lost-to-follow-up/death (AOR 4.4; p = 0.002) but not TBscore (at baseline or change in TBscore 2-months post-treatment) (p = 0.17).

Conclusions

In African HIV-TB co-infected outpatients able to self-expectorate sputum LAM had limited sensitivity even at low CD4 counts, and offered no significant incremental diagnostic yield over Xpert-MTB/RIF or smear microscopy. In primary care clinics with chest radiography and where empiric TB treatment is common, LAM seems unlikely to improve rates of same-day treatment initiation and patient dropout, however, the ability of LAM to identify patients at high risk of death or lost-to-follow-up may offer important prognostic value.

Peer Review reports

Background

Of the estimated 8.6 million active tuberculosis (TB) cases globally an estimated three million cases remained either undiagnosed or unreported [1]. Thus, tests and technologies that allow rapid, accurate, point-of-care (POC) diagnosis represent an unmet need and are projected to substantially reduce the global TB burden [2, 3]. An increasing number of high TB/HIV burden settings are implementing frontline Xpert MTB/RIF testing for HIV-infected patients with suspected TB [4–6], although sputum smear microscopy remains the frontline TB diagnostic tool in the majority of resource-poor high burden settings. Used at the POC, Xpert MTB/RIF can decrease dropout rates (patients TB-positive but not returning to initiate treatment) and time-to-treatment initiation [5, 7]. However, sensitivity in sputum is reduced in HIV-infected patients [8] and is also suboptimal in induced sputum samples [9]. These and other considerations including infrastructure and electricity requirements means that countries remain interested in simple low-cost non-sputum based POC diagnostic tools for both pulmonary and extrapulmonary TB diagnosis.

In 2013, the Alere Determine™ TB LAM Ag lateral flow strip test (Alere, USA, www.alerehiv.com; referred to as LAM from this point forward) became the first commercially available bedside urine test for TB diagnosis in HIV co-infected patients with results available within 25 minutes using just 60ul of urine [10]. To date, diagnostic accuracy studies of urine LAM have been largely single centre [11–13]. Tested patient populations have been heterogeneous (patients with extrapulmonary TB, those unable to spontaneously provide a sputum sample for TB diagnostic testing, or hospitalised patients) [14] and the incremental value of LAM over sputum smear microscopy or Xpert MTB/RIF has thus been variable [11–17]. Nevertheless, POC tests like urine LAM require evaluation in a primary care settings where they are likely to have most impact and where more than 90 % of the TB case load is first encountered. However, there are limited data to guide implementation in such settings where POC TB tests are most needed. Furthermore, the incremental value of LAM over tests like Xpert MTB/RIF, if any, has hardly been studied in HIV endemic primary care settings. There are also limited published data about the potential impact of LAM on morbidity, same-day treatment initiation, patient dropout rates and prognosis [18, 19].

In this study we sought to provide multicentre comparative accuracy and extrapolate impact data of adjunctive LAM testing in the setting where the overwhelming majority of individuals with presumptive pulmonary TB present (out-patient primary care clinics). These data are needed to make a definitive recommendation about the use of LAM in this key patient population. We hypothesised that in out-patients able to self-expectorate sputum for sputum-based diagnostics, LAM would have very limited incremental utility. We therefore tested the urine for LAM positivity in a cohort of 583 HIV-infected patients with suspected pulmonary TB who formed part of a parent randomised controlled trial comparing Xpert MTB/RIF with same-day smear microscopy in primary care clinics of three sub-Saharan African countries [5]. All the participants provided two expectorated sputa and urine sample.

Methods

Design and study population

This cross-sectional accuracy study was nested within a randomised, parallel-arm, multicentre trial, to evaluate the impact of point-of-treatment Xpert MTB/RIF testing with same-day smear microscopy. Patients were enrolled between 12 April 2011 and 1 October 2012. Outpatients ≥18 years that presented to periurban primary-care TB clinics with attached DOTS facilities and microscopy laboratories in Cape Town and Durban (South Africa; laboratory centrally-located), Harare (Zimbabwe), Lusaka (Zambia), and Mbeya (Tanzania) were consecutively enrolled after informed consent. Five Human Research Ethics Committees (HREC) approved the study (University of Cape Town HREC, University of Zambia Biomedical Research Ethics Committee, Mbeya Medical Research Ethics Committee and Medical Research Coordinating Committee of the National Institute for Medical Research, Medical Research Council Durban HREC). Inclusion criteria included: i) symptom(s) of pulmonary TB according to predefined WHO criteria [20, 21] (see online supplementary methods for further details), ii) the ability to spontaneously expectorate two spot sputum specimens with a volume of ≥1 ml each, and exclusion criteria included: i) failure to obtain informed consent and ii) initiation of anti-TB treatment in the previous 60 days. In this sub-study, HIV-uninfected patients were excluded from the analysis. Patients refusing voluntary counselling and testing for HIV (3 %) where considered “positive” and included in the LAM analysis as this would occur in routine clinical practice given the very high (>50 %) incidence of HIV co-infection amongst new TB cases in these endemic countries. A further detailed description of RCT methodology including description of each primary care clinic site is available with the published manuscript of the parent study [5].

Sample collection and processing

Each patient had at least two spot expectorated sputa collected sequentially at recruitment. Nurses visually inspected expectorated sputum samples and estimated the volume using standards of known volume. Patients randomised to the smear microscopy study arm received two same-day sputum smears for acid-fast bacilli and one arbitrarily selected specimen also underwent culture. Patients in the Xpert MTB/RIF arm received nurse-performed clinic-based Xpert MTB/RIF testing and the other specimen was sent for culture. All patients were asked to provide a spontaneously voided urine sample (10–30ml) into a sterile receptacle. Urine was transferred to the laboratory within 4 hours and frozen at -20 degrees for later batch testing. Urine samples were collected in all parent study sites except Zimbabwe where urine biobanking was not possible.

Clinical management and follow-up

Patients were enrolled and initially reviewed by research nursing staff. They were offered voluntary testing and counselling for HIV at recruitment, and received a chest radiograph while awaiting their rapid TB test result. TB-related morbidity was assessed at enrolment and during 2- and 6-month follow-up using the previously validated TBscore [22] (Additional file 1 Table S1 in the online supplement). Patients were referred to the local DOTS programme office at the same clinic for the initiation of anti-TB treatment if any positive result from either smear microscopy, Xpert MTB/RIF, or TB culture result was obtained. Smear-or Xpert MTB/RIF negative patients were referred to clinical staff for review together with their chest radiographs and as part of the routine clinic workflow. The WHO guidelines for the treatment of smear-negative TB [21] are routinely used at each clinic. Doctors who were not part of the study team and routinely visited each facility twice a week initiated the treatment of smear- or Xpert MTB/RIF-negative patients. Follow-up was conducted for all study patients by research staff at 2- and 6-months post randomisation (within a range of 14 days before and after both time points). Patients were considered lost-to-follow up if they were not contactable despite multiple attempts at telephonic contact and a community healthcare worker tracing.

Diagnostic test procedures

Liquid TB culture (Bactec MGIT; BD Microbiology Systems, USA) was performed in central laboratories on sputum decontaminated using N-acetyl-L-cysteine–NaOH. Front-loaded, same-day smear microscopy was performed on-site by a technician employed by the programme in a laboratory attached to the healthcare facility, except in South Africa where it was performed at a centralised laboratory. Fluorescence smear microscopy was performed on concentrated samples with auramine-O staining at all sites except Mbeya, Tanzania where concentrated samples underwent ZN-staining and light microscopy. Patients were classified as having smear-positive tuberculosis on the basis of at least one scanty smear (1–9 bacilli per 100 fields [1000× for light microscopy and 400× for fluorescence microscopy]).

Trained staff, including clinical and laboratory staff, according to the manufacturer recommendations on unprocessed thawed urine specimens stored at -20 degrees for not longer than 18 months, performed LAM strip tests. Two independent readers, blinded to reference test results and clinical outcomes, graded (0–5 according to the colour band intensity) each strip after 25–35 minutes using the pre-January 2014 manufacturer’s reference card (see Additional file 1 Figure S1A in supplement). Where results between the two independent readers were discordant, a third consensus reader graded the LAM strip, and this consensus read was used in the analysis. Further details on the reading of LAM strip tests and the reference cards are provided in the online supplement. LAM strip results were neither provided to the clinicians caring for patients nor were they used for treatment decisions.

Statistical analyses

The reference standard for the primary analysis of diagnostic accuracy was a single sputum liquid culture for Mycobacterium tuberculosis. An additional analysis is provided in the online supplement with culture-negative clinical-TB cases considered reference standard positive given the acknowledged limitation of a single sputum TB culture to diagnose TB in HIV co-infection. The study was powered (75–100 % at 95 % confidence interval) to detect differences in diagnostic accuracy between LAM, Xpert MTB/RIF and smear, alone or in combination, for HIV-infected patients. The study was underpowered to detect small differences in diagnostic accuracy measures amongst different CD4 strata. Descriptive statistics were used to characterise the study population. Diagnostic accuracy measures presented include sensitivity, specificity, positive (LR+, PPV) and negative (LR-, NPV) likelihood ratios and predictive values all with 95 % confidence intervals (CI). χ2 and Fisher’s exact test with mid-P correction were used for comparisons between proportions, and the Mann-Whitney test was used to compare differences in TBscore. The potential impact of same-day LAM testing was assessed by assuming that LAM testing would be performed at the first point of clinic contact and all LAM-positive patients would initiate anti-TB treatment immediately. χ2-squared testing is used to compare same-day treatment initiation and treatment dropout proportions with and without the use of LAM in each study arm. Multivariable- linear (for morbidity scores) and logistic (for mortality) regression analyses were performed. Sample size calculations were based on the primary outcome for the parent study [5] (http://clinicaltrials.gov/show/NCT01554384). Based on the prevalence of HIV and culture-positive TB cases in the parent study there was adequate study power for the 95 % CI around LAM accuracy measures to be within a range of ±10 %. Analyses were performed using OpenEpi (version 2.3.1) [23], and R (version 3.0) [24]. The study is reported in accordance with the STARD initiative recommendations [25].

Role of the funding source

Alere donated the LAM strip tests. However, neither the company nor the study sponsor had any role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results

Study sites and population characteristics

Figure 1 provides the study profile. We enrolled 1095 patients with suspected TB, that were able to provide ≥2 sputa and a spot urine sample, from four primary care clinics in South Africa (n = 419 in Cape Town, n = 193 in Durban), Zambia (n = 400) and Tanzania (n = 83). Further detailed descriptions of each primary care clinic have already been published with the parent study [5]. HIV-infection was confirmed in 564/1095 (52 %) and testing was refused in 19/1095 (1 %); LAM test performance is considered in these two groups combined (N = 583). Of the 583 HIV-positive/status unknown patients with suspected TB, 14 (2 %) had either a contaminated culture or no available result, and 181 (31 %) had culture-positive TB. Table 1 provides the basic demographic and clinical characteristics of the HIV-infected patients of the study population stratified by study site.

Fig. 1
figure 1

Study profile. §LAM testing is not indicated for HIV uninfected patients. #The 19 patients with refusing HIV testing and hence with unknown HIV status are included with HIV-infected patients for the evaluation of LAM performance and potential impact on TB-related morbidity given that this would occur in routine clinical practice. Clinical TB includes any culture-negative patient given anti-tuberculosis treatment (at any point during the 6 month study period) based on either a sputum-positive Xpert MTB/RIF (n = 14) or smear microscopy (n = 11) result, a Chest x-ray suggestive of TB (n = 96) or clinical suspicion alone (n = 6). *1 Smear-positive culture-negative patient did not receive anti-TB treatment and is thus not considered as “Clinical TB diagnosed and treated”. Results of LAM are provided in italics because they were not used for treatment decisions

Full size image
Table 1 Study site and population characteristics
Full size table

LAM performance

Three (<1 %) LAM strip tests failed on the first attempt and required use of a second strip test to produce valid results. The 3rd LAM strip reader was required in 151/583 (26 %) patients, and in 126/151 (83 %) cases this was for differences in grading bands between the grade 0 and 1 intensity. Thus, excluding grade 0 /1 discordance a 3rd reader was required in only 25/583 (4 %) of patients. Additional file 1 Table S2 compares LAM diagnostic accuracy using the grade-2 versus grade-1 cut-point (pre-January 2014 reference card, Fig. 1A) showing the higher specificity and LR+ of the grade-2 cut-point. Inter-observer agreement as to the presence versus absence of a test band of intensity grade 2 or higher was 97.3 % (kappa 0.87), while agreement regarding the presence versus absence of a test band of intensity grade 1 or higher was 90.9 % (kappa 0.77), p < 0.001. Based on this data, and previously published work [14–16, 26] and in accordance with the updated manufacturer’s reference card (see Additional file 1 Figure S1B), the remaining diagnostic accuracy data presented in the results section is presented using the grade-2 LAM cut-point.

Table 2 shows the diagnostic accuracy of LAM, Xpert MTB/RIF and smear-microscopy amongst HIV-infected patients stratified by CD4 cell count (PPV, NPV, LR+ and LR- shown in Additional file 1 Table S3). Overall, LAM had sensitivity (95 % CI) and specificity (95 % CI) of 22.7 % (16.6–28.7) and 93.0 (90.5–95.6) respectively. LAM specificity did not significantly increase when TB culture-negative patients diagnosed with clinical-TB were considered reference test positive in a secondary analysis [95.4 % (92.1–97.4) versus 93.0 (90.5–95.6), p = 0.2, Additional file 1 Table S4]. LAM specificity was significantly higher at South African compared to Zambian and Tanzanian study sites, both in the primary and secondary analyses [Primary analysis: Cape Town: 99.0 % and Durban: 97.9 % compared to Lusaka: 87.1 % and Mbeya: 89.7 %, p < 0.001 for comparisons between SA sites and Lusaka and p < 0.05 for comparisons between SA sites and Mbeya] (see online Additional file 1 Table S5B and C)]. LAM strip sensitivity (95 % CI) was not significantly higher in CD4 ≤ 100 versus >100cell/mm3 [30.4 % (17.1–43.7) versus 18.3 % (12.5–25.9), p = 0.085], while specificity was similar.

Table 2 Key diagnostic accuracy measures of LAM (grade 2 cut-point), sputum Xpert MTB/RIF or smear microscopy alone or in combination for culture-confirmed versus culture-negative pulmonary tuberculosis amongst HIV-infected (and refused testing) patients stratified by CD4 cell count
Full size table

LAM testing compared to Xpert MTB/RIF or smear microscopy

The overall sensitivity (95 % CI) of Xpert MTB/RIF (76.1 %, 70/92) was significantly higher than either LAM (22.7 %, 41/181) or smear microscopy (43.8 %, 39/89) (p < 0.001 for both comparisons); similarly in patients with CD4 ≤ 100 cells/mm3 Xpert MTB/RIF (76.2 %, 16/21) offered higher sensitivity than either LAM (30.4 %, 14/46, p < 0.001) or smear microscopy (36 %, 9/25, p = 0.006). Xpert MTB/RIF had the highest test LR+ (95 % CI) of 10.7 (9.2–12.4) and correspondingly a PPV (95 % CI) of 83.3 % (74.0–89.8). Overall, but not in patients with CD4 ≤ 100 cells/mm3, smear microscopy (43.8 %, 39/89) offered significantly higher sensitivity compared to LAM alone (22.7 %, 41/181, p < 0.001). Similar differences in test sensitivities were seen across all study sites except in Durban where LAM (40 %), sputum Xpert MTB/RIF (60 %) and smear microscopy (50 %) offered similar sensitivities (online Additional file 1 Table S5A). Specificity of LAM (93.0 %), Xpert MTB/RIF (92.9 %) and smear microscopy (93.2 %) used alone was similar irrespective of CD4 strata (p > 0.05 for all comparisons).

LAM in combination with either sputum-based MTB/RIF or smear microscopy

The diagnostic accuracy of using LAM in combination with either sputum-based Xpert MTB/RIF or smear-microscopy is also shown in Table 2. LAM plus Xpert MTB/RIF (72/92, 78.3 %) did not offer significantly better sensitivity to Xpert MTB/RIF alone (70/92, 76.1 %) (p = 0.7). Similarly, LAM plus smear microscopy (50/89, 56.2 %) did not offer significantly better sensitivity to smear microscopy alone (39/89, 43.8 %) (p = 0.1). In contrast, the specificity of LAM plus Xpert MTB/RIF (169/196, 86.2 %) was significantly lower than either LAM strip (361/388, 93.0 %) or Xpert MTB/RIF (182/189, 92.9 %) testing alone (p = 0.007 versus LAM and p = 0.032 versus Xpert MTB/RIF), and these relationships were unchanged if the analysis was restricted to patients with CD4 ≤ 100 cells/mm3. For LAM plus smear microscopy, the overall specificity (172/192, 89.6 %) did not differ significantly compared to either LAM (361/388, 93.0 %) or smear (179/192, 93.2 %) alone (p > 0.05 for both comparisons), however, in patients with CD4 ≤ 100 cells/mm3 combined specificity was lower than LAM testing alone (93.0 %) (p = 0.037). The specificity relationships were unchanged in the secondary analysis (Additional file 1 Table S4).

A sensitivity analysis was performed to investigate the impact of the 21 % (28/131) and 27 % (36/130) Non-TB patients in the smear and Xpert study arms respectively that were lost-to-follow up and the 1.5 % (2/131) and 3 % (4/130) that were deceased. No differences in the diagnostic accuracy of LAM alone or with smear/Xpert were noted (data not shown).

Potential impact on patient-important treatment outcomes of adding point-of-care LAM to sputum-based Xpert MTB/RIF or smear microscopy

In the parent study, the reason for treatment initiation, time-to-treatment and failure to initiate treatment in culture-positive TB patients (‘dropout’) was recorded (Fig. 2). The potential impact on these outcomes of adding point-of-care LAM (in the manner described in methods section) is also shown in Fig. 2. In the smear microscopy study arm with the use of empiric treatment based on CXR, use of POC LAM would neither have significantly decreased dropout [18 % (16/89) to 12 % (11/89), p = 0.3], nor significantly increased same-day treatment initiation [35 % (31/89) to 44 % (39/89), p = 0.2]. However, in primary care settings without same-day CXR facilities, POC LAM would have significantly increased same-day treatment initiation [24 % (21/89) to 44 % (39/89, p = 0.004]. Potentially unnecessary treatment initiation would have increased by 3 % (4/116) due to LAM ‘false-positives’. In the Xpert MTB/RIF study arm, LAM would neither have significantly decreased treatment dropout [11 % (10/92) to 10 % (9/92), p = 0.8] nor significantly increased same-day treatment initiation [55 % (51/92) to 57 % (52/92), p = 0.9]. However, potentially unnecessary treatment initiation would have increased by 7 % (7/106) due to LAM ‘false-positives’.

Fig. 2
figure 2

Treatment outcomes in each study arm indicating the potential impact of LAM in TB culture positive patients. a Smear-microscopy b clinic-based Xpert MTB/RIF testing. ‘False-positives’: These indicate patients that were sputum culture-negative, smear or Xpert MTB/RIF-negative and not given empiric TB treatment by the attending clinician that would have been LAM positive. These patients would have thus received inappropriate anti-TB treatment

Full size image

LAM as a potential prognostic marker

Table 3 shows all cause 6-month mortality, lost-to-follow-up and TBscore at enrolment amongst HIV-infected/status unknown patients stratified by LAM result. LAM strip positive versus negative patients had: i) higher all cause 6-month mortality [25 % versus 11 %, P = 0.02], ii) higher lost-to-follow-up [54 % versus 30 %, p < 0.001], and iii) a higher baseline TB-related morbidity score [7 (6–8) versus 5 (4–7), p = 0.03]. However, in the multivariate analyses shown in Table 4, LAM positivity was only a predictor of the combined outcome of lost-to-follow-up/death but not 6-month mortality or baseline TBscore. In addition, TB-related morbidity outcomes, as measured by the amount of improvement from enrolment in TB-score at 2- and 6-months post-initiation of effective anti-TB treatment were similar amongst LAM strip positive versus negative patients [4(3–5) versus 4 (2.5–5), p = 0.136] (online Additional file 1 Table S6).

Table 3 Morbidity (measured by TBscore), 6-month all cause mortality and lost-to-follow up stratified by baseline results of LAM in HIV-infected (or test refused) patientsa
Full size table
Table 4 Multivariate analysis showing predictors of all-cause mortality, lost-to-follow-up/mortality and baseline TB-related morbidity in HIV-infected patients overall and restricted to culture-positive TB patients onlya
Full size table

Discussion

In this multi-centre out-patient study of patients with suspected PTB able to provide expectorated sputum for diagnostic testing, LAM had poor overall sensitivity, which did not significantly improve in patients with CD4 cell counts less than 100 cells/ml. LAM was not able to improve on the diagnosis offered by either sputum-based Xpert MTB/RIF or smear microscopy alone. Due to this lack of incremental utility over sputum-based tools, LAM seems unlikely to be able to improve outpatient important treatment outcomes. Indeed, although LAM could offer some prognostic utility in identifying patients at high risk of death or loss-to-follow-up, there was no impact on patient dropout or morbidity. Adjunctive LAM testing may only increase same-day treatment initiation in clinic settings using sputum smear microscopy where same-day chest radiography is not available to guide empiric same-day treatment decisions. It may be argued that our study only considered outpatients able to expectorate sputum, and LAM may offer important incremental value for patients unable to provide sputum for diagnostic testing. However, this study’s patient population is the major subgroup presenting to primary care facilities for frontline testing and although preliminary data suggest that this is not the subgroup most likely to benefit from LAM, data is nevertheless essential for clear recommendations to guide implementation across TB programs. Indeed, program directors continue to question why the only commercially available and affordable POC TB test is unavailable for frontline testing? The data outlined here offers valuable insights.

Published data, albeit limited, indicate that LAM sensitivity is increased with higher circulating LAM levels, occurring with higher mycobacterial disease burden, extrapulmonary TB, lower CD4 cell count and WHO clinical stage 3 and 4 in out- and in-patient settings [11, 27–34]. Moreover, LAM and sputum smear microscopy identified non-overlapping sub-groups of culture-positive TB, thereby offering additive diagnostic value [11–14, 16, 35]. By contrast, we found no incremental benefit of LAM. There are a number of possible explanations. Firstly, sputum-scarce TB, smear-negative TB, and EPTB is more common in hospital-based and pre-ART screening cohorts and thus smear microscopy sensitivity is more likely to be reduced, which in turn would increase the incremental benefit offered by LAM testing. Secondly, differences in sputum smear microscopy staining and concentration methodologies across different studies affect smear microscopy sensitivity [13]. Thirdly, in contrast to other LAM-based studies [11, 12, 14] our study did not offer sputum induction to improve sputum sampling and thus, those unable to spontaneously produce two spot sputa were excluded. Sputum induction was not offered as the pragmatic study design of the parent study reflects the reality that sputum induction facilities remain unavailable in the majority of routine primary care clinic settings. Nevertheless, the inability of LAM testing to improve the diagnostic yield of a single sputum-based Xpert MTB/RIF, irrespective of declining CD4 cell count, is consistent with the findings of Lawn et al. and reflect the superior sensitivity of sputum-based Xpert MTB/RIF for the diagnosis of pulmonary TB [11, 36, 37].

In our initial study of LAM amongst hospitalised HIV-infected patients with advanced immunosuppression we noted that test specificity and inter-reader agreement was optimised (>95 % for both) by use of an alternative grade-2 rather than the manufacturer’s initially suggested grade-1 cut-point [16]. Based on these findings, the manufacturer’s reference card has been updated as of January 2014 so that the first positive visual band corresponds to the grade-2 intensity band of the old reference card (see Fig. 1 of the online supplement, www.alere.com).

Independent of cut-point selection, suboptimal LAM specificity (<95 % as recommended by an expert committee for point-of-care TB testing [38]), particularly in countries north of South Africa, remains a concern. Indeed we noted lower test specificity in Tanzania and Zambia compared to the two South African study sites. Reasons for this may include different degrees of the unavoidable misclassification bias associated with a single sputum culture to correctly classify TB in HIV-infected patients with advancing immunosuppression. However, in our secondary analysis excluding ‘probable or clinical TB’ the specificity in Zambia and Mbeya remained lower. Kroidl et al. found cross-contamination of the LAM ELISA from dust, soil and stool in Tanzania, and we have demonstrated cross-reacting LAM-like glycolipid antigens in Nocardia and Candida spp. [30, 39]. Sterile collection of urine samples is essential, especially in countries north of South Africa, and in a recent Ugandan in- and out-patient study LAM specificity was 95 % [14].

LAM offered limited incremental diagnostic benefit over sputum-based diagnostics. In contrast to studies showing incremental benefit of LAM in hospitalised patients with sputum-scarce TB and EPTB [14, 16] or those identifying patients with TB missed by empiric treatment initiation but identified by LAM [40]. Consequently, our study suggests LAM would have minimal potential impact on patient important treatment outcomes. In fact, test specificity was significantly lower when combining Xpert MTB/RIF with LAM for both a culture and composite reference standard with the potential to increase inappropriate treatment initiation. Thus, sputum-based diagnosis, especially where Xpert MTB/RIF is available, should be preferred in HIV-infected outpatients able to spontaneously provide sputa. However, LAM may potentially improve same-day treatment initiation in the clinic setting where only sputum smear microscopy is performed and no chest radiography facilities are available. In addition, LAM may still offer i) important added diagnostic benefit where the performance of sputum-based tests is reduced such as sputum-scarce TB, extrapulmonary TB, mycobacteremia [27], and/ or renal TB [41], and ii) important prognostic and treatment monitoring utility [18].

This study had several limitations and strengths. It is the first large multicentre study in primary care practice, allowing for accurate evaluation of diagnostic accuracy across three sub-Saharan African countries. The design of the parent study offered a unique opportunity to evaluate the diagnostic accuracy of LAM in a well-defined out-patient population able to provide sputum for diagnostic testing and hence, to estimate the potential impact of LAM when combined with either Xpert MTB/RIF or smear in this patient group. Misclassification bias was a potential problem in our study as a single sputum culture can miss TB cases amongst HIV-infected patients. However, in an alternative analysis where TB culture-negative patients diagnosed as clinical TB and initiating treatment are considered the reference test, no significant difference in LAM specificity was noted and study conclusions were unaltered. In addition, a sensitivity analysis with lost-to-follow-up and deceased patients excluded from the non-TB group i.e. considered unclassifiable, did not significantly alter diagnostic accuracy measures. LAM was performed on frozen rather than fresh samples which could have reduced test sensitivity, however, meta-analysis data suggests no differences in diagnostic accuracy using frozen rather than fresh samples [42]. Consequently, impact data for adjunctive LAM is extrapolated. The study was not powered to detect small differences in sub-groups (CD4 strata, treatment dropouts) and thus small incremental benefits of LAM in these sub-groups may not have been detected. Likewise, the small number of study deaths limited power to examine LAM as a predictor of mortality in the multivariate analysis.

In conclusion, LAM strip testing had poor sensitivity amongst HIV-infected outpatients able to provide expectorated sputum for diagnostic testing. There was no incremental diagnostic benefit over either Xpert MTB/RIF or smear microscopy. If used as an adjunctive diagnostic tool in this setting, it is unlikely to impact patient-important treatment outcomes such as morbidity, patient dropout, or same-day treatment initiation, except in smear microscopy only clinics with no chest radiography. Potential gains need to be weighed against the likely increase in inappropriate ‘false-positive’ treatment. However, further impact-orientated studies focused on mortality and morbidity benefits in ill hospitalised patients are warranted.

Abbreviations

LAM:

Lipoarabinomannan. In manuscript used as abbreviation for DetermineTM TB LAM Ag lateral flow strip test (Alere, USA)

HIV:

Human immunodeficiency virus

TB:

Tuberculosis

EPTB:

Extra-pulmonary tuberculosis

Xpert MTB/RIF:

GeneXpert MTB/RIF assay (Cepheid, USA)

POC:

Point-of-care

DOTS:

Directly observed Treatment Short-course

WHO:

World Health Organisation

RCT:

Randomised controlled trial

MGIT:

Microscopic growth in-tube

NaOH:

Sodium hydroxide

ZN:

Ziehl-Neelsen

CD4:

CD4 T-cell count

LR+:

Positive likelihood ratio

PPV:

Positive predictive value

LR-:

Negative likelihood ratio

NPV:

Negative predictive value

ELISA:

Enzyme linked immunosorbent assay

References

  1. WHO. WHO Report 2013: Global tuberculosis control. Geneva: World Heath Organisation; 2013. ISBN 978 92 4 156438 0.

    Google Scholar 

  2. Dowdy DW, Chaisson RE, Moulton LH, Dorman SE. The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model. AIDS. 2006;20(5):751–62.

  3. Lin HH, Dowdy D, Dye C, Murray M, Cohen T. The impact of new tuberculosis diagnostics on transmission: why context matters. Bull World Health Organ. 2012;90(10):739–47A. doi:10.2471/blt.11.101436. Epub 2012/10/31

    Article  PubMed  PubMed Central  Google Scholar 

  4. Yoon C, Cattamanchi A, Davis JL, Worodria W, den Boon S, Kalema N, et al. Impact of Xpert MTB/RIF testing on tuberculosis management and outcomes in hospitalized patients in Uganda. PLoS One. 2012;7(11), e48599. doi:10.1371/journal.pone.0048599.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2014;383(9915):424–35. doi:10.1016/S0140-6736(13)62073-5.

    Article  CAS  PubMed  Google Scholar 

  6. Hanrahan CF, Selibas K, Deery CB, Dansey H, Clouse K, Bassett J, et al. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg. South Africa PLoS One. 2013;8(6), e65421. doi:10.1371/journal.pone.0065421.

    Article  CAS  PubMed  Google Scholar 

  7. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011;377(9776):1495-505. Epub 2011/04/22. doi:10.1016/S0140-6736(11)60438-8.

  8. Theron G, Peter J, Dheda K. Xpert MTB/RIF test for tuberculosis. Lancet. 2011;378(9790):481. doi:10.1016/S0140-6736(11)61242-7. author reply 2-3. Epub 2011/08/09.

    Article  PubMed  Google Scholar 

  9. Peter JG, Theron G, Singh N, Singh A, Dheda K. Sputum induction to aid diagnosis of smear-negative or sputum-scarce tuberculosis in adults in HIV-endemic settings. Eur Respir J. 2014;43(1):185–94. doi:10.1183/09031936.00198012.

    Article  PubMed  Google Scholar 

  10. Alere. Alere Determine TB LAM Ag 2014 [cited 2014 7th April 2014]. Available from: http://www.alere.com/ww/en/product-details/determine-tb-lam.html.

  11. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis. 2012;12(3):201–9. doi:10.1016/S1473-3099(11)70251-1.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Drain PK, Losina E, Coleman SM, Giddy J, Ross D, Katz JN, et al. Diagnostic accuracy of a point-of-care urine test for tuberculosis screening among newly-diagnosed hiv-infected adults: a prospective, clinic-based study. BMC Infect Dis. 2014;14(1):110. doi:10.1186/1471-2334-14-110. Epub 2014/02/28.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Balcha TT, Winqvist N, Sturegard E, Skogmar S, Reepalu A, Jemal ZH, et al. Detection of lipoarabinomannan in urine for identification of active tuberculosis among HIV-positive adults in Ethiopian health centres. Tropical medicine & international health : TM & IH. 2014. doi:10.1111/tmi.12308.

  14. Nakiyingi L, Moodley VM, Manabe YC, Nicol MP, Holshouser M, Armstrong DT, et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults. J Acquir Immune Defic Syndr. 2014. Epub 2014/03/29. doi:10.1097/qai.0000000000000151.

  15. Lawn SD, Dheda K, Kerkhoff AD, Peter JG, Dorman S, Boehme CC, et al. Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies. BMC Infect Dis. 2013;13:407. doi:10.1186/1471-2334-13-407.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Peter JG, Theron G, van Zyl-Smit R, Haripersad A, Mottay L, Kraus S, et al. Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J. 2012;40(5):1211–20. doi:10.1183/09031936.00201711. Epub 2012/03/01.

    Article  PubMed  Google Scholar 

  17. Shah M, Ssengooba W, Armstrong D, Nakiyingi L, Holshouser M, Ellner JJ, et al. Comparative performance of urinary lipoarabinomannan assays and Xpert MTB/RIF in HIV-infected individuals with suspected tuberculosis in Uganda. AIDS. 2014. Epub 2014/03/19. doi:10.1097/qad.0000000000000264.

  18. Drain PK, Grobler A, Gounder L, Sahid F, Wilson D, Bassett IV, et al. Rapid urine lipoarabinomannan testing after two months of tuberculosis treatment independently predicts mortality in a resource-limited setting. 44th Union World Conference on Lung Health; December, 2013. Paris: The International Journal of Tuberculosis and Lung Disease; 2013. p. S264.

    Google Scholar 

  19. Drain PK, Grobler A, Gounder L, Sahid F, Wilson D, Bassett IV, et al. Point-of-care urine lipoarabinomannan for diagnosis and treatment response of pulmonary tuberculosis in sputum smear-negative suspects. Int J Tuberc Lung Dis. 2013;17(12):S277.

    Google Scholar 

  20. Aderaye G. Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents: recommendations for HIV-prevalent and resource-constrained settings: World Health Organization; 2007.

  21. Getahun H, Harrington M, O’Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet. 2007;369:2042–9.

    Article  PubMed  Google Scholar 

  22. Wejse C, Gustafson P, Nielsen J, Gomes VF, Aaby P, Andersen PL, et al. TBscore: Signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course. Scand J Infect Dis. 2008;40(2):111–20. doi:10.1080/00365540701558698.

    Article  PubMed  Google Scholar 

  23. Dean AG SK, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 2.3.1. http://www.OpenEpi.com, updated 2010/19/09, accessed 2010/11/30.

  24. Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2005. ISBN 3-900051-07-0.

    Google Scholar 

  25. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med. 2003;138(1):W1-12. Epub 2003/01/07. doi: 200301070-00012-W1.

  26. Peter JG, Theron G, Dheda K. Urine antigen test for diagnosis of HIV-associated tuberculosis. Lancet Infect Dis. 2012;12(11):825. doi:10.1016/s1473-3099(12)70220-7. author reply 6-7. Epub 2012/10/27.

    Article  PubMed  Google Scholar 

  27. Shah M, Martinson NA, Chaisson RE, Martin DJ, Variava E, Dorman SE. Quantitative analysis of a urine-based assay for detection of lipoarabinomannan in patients with tuberculosis. J Clin Microbiol. 2010;48(8):2972–4. doi:10.1128/jcm.00363-10. Epub 2010/06/11.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Talbot E, Munseri P, Teixeira P, Matee M, Bakari M, Lahey T, et al. Test characteristics of urinary lipoarabinomannan and predictors of mortality among hospitalized HIV-infected tuberculosis suspects in Tanzania. PLoS One. 2012;7(3):e32876. doi:10.1371/journal.pone.0032876. Epub 2012/03/14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Gounder CR, Kufa T, Wada NI, Mngomezulu V, Charalambous S, Hanifa Y, et al. Diagnostic Accuracy of a Urine Lipoarabinomannan Enzyme-Linked Immunosorbent Assay for Screening Ambulatory HIV-Infected Persons for Tuberculosis. J Acquir Immune Defic Syndr. 2011;58(2):219–23. doi:10.1097/QAI.0b013e31822b75d4. Epub 2011/07/19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Dheda K, Davids V, Lenders L, Roberts T, Meldau R, Ling D, et al. Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples. PLoS One. 2010;5(3), e9848. doi:10.1371/journal.pone.0009848. Epub 2010/03/31.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Mutetwa R, Boehme C, Dimairo M, Bandason T, Munyati SS, Mangwanya D, et al. Diagnostic accuracy of commercial urinary lipoarabinomannan detection in African tuberculosis suspects and patients. Int J Tuberc Lung Dis. 2009;13(10):1253–9. Epub 2009/10/02.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Daley P, Michael JS, Hmar P, Latha A, Chordia P, Mathai D, et al. Blinded evaluation of commercial urinary lipoarabinomannan for active tuberculosis: a pilot study. Int J Tuberc Lung Dis. 2009;13(8):989–95. Epub 2009/09/03.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Reither K, Saathoff E, Jung J, Minja LT, Kroidl I, Saad E, et al. Low sensitivity of a urine LAM-ELISA in the diagnosis of pulmonary tuberculosis. BMC Infect Dis. 2009;9:141.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker LG, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS. 2009;23(14):1875–80. Epub 2010/01/29.

    Article  PubMed  Google Scholar 

  35. Drain PK, Losina E, Coleman SM, Giddy J, Ross D, Katz JN, et al. Value of urine lipoarabinomannan grade and second test for optimizing clinic-based screening for HIV-associated pulmonary tuberculosis. J Acquir Immune Defic Syndr. 2015;68(3):274–80. doi:10.1097/QAI.0000000000000436.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Theron G, Peter J, van Zyl-Smit R, Mishra H, Streicher E, Murray S, et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med. 2011;184(1):132–40. doi:10.1164/rccm.201101-0056OC.

    Article  PubMed  Google Scholar 

  37. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. The Cochrane Database Syst Rev. 2014;1:CD009593. doi:10.1002/14651858.CD009593.pub3.

    PubMed  Google Scholar 

  38. Treatment Action Group MSF. Paris meeting on TB point-of-care test specifications. 2009.

  39. Kroidl I, Clowes P, Mwakyelu J, Maboko L, Kiangi A, Rachow A, et al. Reasons for false-positive lipoarabinomannan ELISA results in a Tanzanian population. Scand J Infect Dis. 2014;46(2):144–8. doi:10.3109/00365548.2013.853133. Epub 2013/11/28.

    Article  CAS  PubMed  Google Scholar 

  40. Peter JG, Theron G, Dheda K. Can point-of-care urine LAM strip testing for tuberculosis add value to clinical decision making in hospitalised HIV-infected persons? PLoS One. 2013;8(2):e54875. doi:10.1371/journal.pone.0054875. Epub 2013/02/08.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Peter JG, Theron G, Muchinga TE, Govender U, Dheda K. The diagnostic accuracy of urine-based Xpert MTB/RIF in HIV-infected hospitalized patients who are smear-negative or sputum scarce. PLoS One. 2012;7(7):e39966. doi:10.1371/journal.pone.0039966.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Minion J, Leung E, Talbot E, Dheda K, Pai M, Menzies D. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. Eur Respir J. 2011;38(6):1398–405. doi:10.1183/09031936.00025711. Epub 2011/06/28.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We are indebted to the patients who participated in this study. We thank the Health Directorate of the City of Cape Town, the Zambian Ministry of Health, the Kwa-Zulu Natal Provincial Department of Health, and the Tanzanian Ministry of Health and Social Welfare. We acknowledge the assistance of health facility staff at each site, and the assistance of the local institutional review boards.

The TB-NEAT study team

Field team: M Pretorius, M Pascoe, B Soetwater, M Wyngard, L Pool (Cape Town); C Viny, M Kasonde, L Manjeta (Lusaka); T Mthiyane, N Ntshuba, S Gumede, T Mvuyane, P Mbambo (Durban); C Mangu, F Kayombo, A Temihanga, M Kimaro, B Mnyanyi, I Mgogo, B Ambukege, T Sanga (Mbeya). Laboratory team: R Meldau, V Woodbourne, P Hope (Cape Town); J Mzyece (Lusaka); F Madaar (Durban); F Kayombo, H Mbilinyi, G. Rojas-Ponce, D Mapamba, C Lueer, A Bauer, L Njovu (Mbeya). Data team: D Cogill, V Louw (Cape Town); V Kapotwe (Lusaka); C Connolly (Durban); D Kowuor, N Chiwerengo, S Edwards (Mbeya).

Author information

Author notes

    Authors and Affiliations

    1. Lung Infection and Immunity Unit, Division of Pulmonology & UCT Lung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa

      Jonny Peter, Grant Theron, Duncan Chanda & Keertan Dheda

    2. TB Vaccine group, Jenner Institute, University of Oxford, Oxford, UK

      Jonny Peter

    3. Institute for Medical Research & Training (IMReT), University Teaching Hospital, Lusaka, Zambia

      Duncan Chanda & Peter Mwaba

    4. National Institute of Medical Research, Mbeya Medical Research Centre, Mbeya, Tanzania

      Petra Clowes

    5. Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich (LMU), Munich, Germany

      Petra Clowes, Andrea Rachow & Michael Hoelscher

    6. German Centre for Infection Research (DZIF), Munich, Germany

      Andrea Rachow & Michael Hoelscher

    7. Department of Medicine, University of Cape Town, Cape Town, South Africa

      Jonny Peter & Maia Lesosky

    8. South African Medical Research Council, Durban, South Africa, KwaZulu Research Institute for Tuberculosis and HIV (K-RITH), Durban, South Africa

      Alex Pym

    9. Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa

      Keertan Dheda

    Authors
    1. Jonny Peter
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Grant Theron
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Duncan Chanda
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Petra Clowes
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Andrea Rachow
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Maia Lesosky
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Michael Hoelscher
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Peter Mwaba
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Alex Pym
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Keertan Dheda
      View author publications

      You can also search for this author in PubMed Google Scholar

    Consortia

    For the TB-NEAT team

    Corresponding author

    Correspondence to Keertan Dheda.

    Additional information

    Competing interests

    Although Alere supplied the ELISA and LAM strip-tests free of charge they had no role in the design and conduct of the study, analysis of the data or writing of the manuscript. The authors have no other interests to declare.

    Authors’ contribution

    Conception and design: JP, GT, DC, PC, AR, MH, PMw, AP, KD. Study implementation: GT, JP, KD, AP, DC, PMw, AR, PC, MH. Analysis: GT, JP, DC, ML, KD. Interpretation and important intellectual input: GT, JP, DC, KD. First draft: JP, GT, DC, KD. All authors read and approved the final manuscript.

    Jonny Peter, Grant Theron and Duncan Chanda contributed equally to this work.

    Additional file

    Additional file 1: Figure S1A.

    Pre-January 2014 LAM strip test manufacturer’s reference card illustrating visual intensity grades 0-5. Figure S1B: January 2014 new LAM strip test manufacturer’s reference card illustrating visual intensity grades 0-4. Table S1. Variables used to calculate the TB score as defined by Wejse et al. (2008)1. Each patient was scored at baseline, 2 months and 6 months. Table S2. Comparative diagnostic accuracy of two LAM strip test grade cut-points (old reference card) in HIV-infected patients and stratified by CD4 cell count. Table S3. Additional diagnostic accuracy measures (Likelihood ratios and predictive values) of LAM (grade 2 cut-point), sputum Xpert MTB/RIF or smear microscopy alone or in combination for culture-confirmed versus culture-negative pulmonary tuberculosis amongst HIV-infected (and refused testing) patients stratified by CD4 cell count (TB prevalence = 31 %). Table S4. Diagnostic accuracy of LAM (grade 2 cut-point) alone or in combination with either Xpert MTB/RIF or smear microscopy for culture-positive and clinical versus culture-negative pulmonary tuberculosis amongst HIV-infected (and refused testing) patients and stratified by CD4 cell count. Table S5A. Sensitivity of different diagnostic tests alone and in combination in HIV-infected (and refused testing) patients with culture-positive tuberculosis, stratified by study site. Table S5B. Specificity of different diagnostic tests alone or in combination in all patients culture-negative for tuberculosis, stratified by study site. Table S5C. Specificity of different diagnostic tests alone or in combination in HIV-infected patients culture-negative for tuberculosis and without clinical TB stratified by study site. Table S6. Changes in 2-month and 6-month TB-related morbidity indices in patients treated for TB according to baseline culture status, stratified by LAM result.

    Rights and permissions

    Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

    The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

    To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

    The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Peter, J., Theron, G., Chanda, D. et al. Test characteristics and potential impact of the urine LAM lateral flow assay in HIV-infected outpatients under investigation for TB and able to self-expectorate sputum for diagnostic testing. BMC Infect Dis 15, 262 (2015). https://doi.org/10.1186/s12879-015-0967-z

    Download citation

    • Received:

    • Accepted:

    • Published:

    • DOI: https://doi.org/10.1186/s12879-015-0967-z

    Keywords

    BMC Infectious Diseases

    ISSN: 1471-2334

    Contact us